ALSO NOTED: Arqule hires new CEO; Kosan launches mid-stage study; and much more...

> Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug companies just like they've bought up Manhattan condos. Report

> Chutes & Ladders: Arqule has hired Paolo Pucci, currently president of the Bayer-Schering Pharmaceuticals Global Oncology/Specialized Therapeutics divisions, as its new CEO. Pucci is taking over in June, following Stephen Hill, who was named the new CEO of Solvay. Report

> Kosan Biosciences has launched a mid-stage study of an experimental therapy for non-small cell lung cancer. Release

> Innogenetics has completed a $9.5 million settlement and licensing agreement with U.S. group Abbott Laboratories, ending a lawsuit. Story

> Medivir has entered into a co-promotions deal with GlaxoSmithKline for the Swedish market. Release

> AstraZeneca investors were jumping for joy this morning when the drugmaker announced it had played Let's Make a Deal with Indian generics maker Ranbaxy. Report

> Remember that drug-safety database Congress required the FDA to set up? Well, the agency is ready to announce its plans--and they don't include setting up a database. Instead, the FDA will contract with insurers, such as WellPoint and UnitedHealth. Report

> A few prominent research doctors are saying "No, thanks," to any payments from drug and device companies. Report

> The FDA's China office is slated to open next month. Report

And Finally... Contrary to what most of us would like to believe, decision-making may be a process handled to a large extent by unconscious mental activity. Release

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.